Saturday, February 3, 2018

Shingles Vaccination―Shingrix vs Zostavax

Recently, Singles vaccination has been brought back to the front page:
New Shingles Vaccine Shows Efficacy for Older Adults

Shingrix® vs Zostavax®


Basically, the excitements are all about the new shingles vaccine named Shingrix:
In October 2017, the U.S. Food and Drug Administration (FDA) licensed the Shingrix® vaccine for adults aged 50 years and older to prevent shingles. The CDC recommends two doses of Shingrix, two to six months apart for healthy adults aged 50 and older.
On Oct. 25, the Advisory Committee on Immunization Practices (ACIP) voted that Shingrix is the preferred vaccine for preventing shingles and related complications. It is also recommended for adults who previously received the current shingles vaccine (Zostavax®).
This seems to be good news to elderly individuals because:
  1. Shingrix is recommended for healthy adults aged 50 and older while current shingles vaccine Zostavax® is only recommended for adults aged 60 and older
    • Elderly individuals do not respond to immune challenge as robustly as the young.[3]
  2. In such a short time, Shringrix® has been voted as the preferred vaccine by ACIP

Precautions


As always, all vaccines could have possible side effects and might not be good for all adults.  Using current  shingles vaccine (Zostavax®) as an example, you can find those information in the "Vaccine Consent and Administration Record" of the attached form.

For more details on "Shingles",  please read below article:
Shingles and Its Remedies


References



No comments:

Post a Comment